Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2022 | Unmet needs of immunotherapy for bladder cancer

Prantik Das • 18 Feb 2022
GU Cancers 2022
Bladder Cancer Genitourinary Cancer Urothelial Carcinoma

Prantik Das, MBBS, MRCP, FRCR, PG Dip, UHDB NHS Foundation Trust, Derby, UK and University of Nottingham, Nottingham, UK, discusses some of the challenges of immunotherapy in clinical practice for bladder cancer. This interview took place at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium 2022 in San Francisco, CA.

More from Prantik Das

1:12
Unmet clinical needs in bladder cancer care in the UK
Prantik Das • 18 Feb 2022
2:12
Real-world study of atezolizumab vs. pembrolizumab for advanced/metastatic UC
Prantik Das • 18 Feb 2022
2:28
Hypofractionated radiotherapy for the management of prostate cancer
Prantik Das • 8 Mar 2019
3:14
The benefits of using patient reported outcomes in prostate cancer
Prantik Das • 8 Mar 2019

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals